To test this concept, we further evaluated the prediction performance of IFN-γ/IMS on two publicly available RNA-seq datasets with pretreatment samples from melanoma patients treated with anti-CTLA-4 therapy (VanAllen15; n = 42)40 and metastatic gastric cancer patients treated with anti-PD-1 therapy (Kim18; n = 45)41. The gene discussed is IFNG; the disease is melanoma.